These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. The use of Duloxetine in the treatment of male stress urinary incontinence. Fink KG; Huber J; Würnschimmel E; Schmeller NT Wien Med Wochenschr; 2008; 158(3-4):116-8. PubMed ID: 18330528 [TBL] [Abstract][Full Text] [Related]
48. Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion. Krebs J; Pannek J Spinal Cord; 2013 Apr; 51(4):306-9. PubMed ID: 23247012 [TBL] [Abstract][Full Text] [Related]
49. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M; Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951 [TBL] [Abstract][Full Text] [Related]
50. Darifenacin in the treatment of overactive bladder. Haab F Drugs Today (Barc); 2005 Jul; 41(7):441-52. PubMed ID: 16193097 [TBL] [Abstract][Full Text] [Related]
51. Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q). Gotoh M; Kobayashi T; Sogabe K Int J Urol; 2014 May; 21(5):505-11. PubMed ID: 24304092 [TBL] [Abstract][Full Text] [Related]
52. [Conservative treatment in male urinary incontinence]. Kirschner-Hermanns R; Anding R Urologe A; 2014 Mar; 53(3):333-4, 336, 338. PubMed ID: 24585116 [TBL] [Abstract][Full Text] [Related]
53. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M; BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143 [TBL] [Abstract][Full Text] [Related]
54. Pharmacological treatment of pure stress urinary incontinence: a narrative review. Malallah MA; Al-Shaiji TF Int Urogynecol J; 2015 Apr; 26(4):477-85. PubMed ID: 25630399 [TBL] [Abstract][Full Text] [Related]
55. Solifenacin in women with de novo overactive bladder after tension-free obturator vaginal tape--is it effective? Serati M; Braga A; Sorice P; Siesto G; Salvatore S; Ghezzi F J Urol; 2014 May; 191(5):1322-6. PubMed ID: 24148761 [TBL] [Abstract][Full Text] [Related]
56. Co-administration of an α(1) -blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity. Nagase K; Ito H; Aoki Y; Tanase K; Akino H; Yokoyama O Int J Urol; 2011 Dec; 18(12):836-43. PubMed ID: 21995543 [TBL] [Abstract][Full Text] [Related]
57. [Pharmacological treatment for stress urinary incontinence in prostate cancer]. Puyol M; Collado A Arch Esp Urol; 2009 Dec; 62(10):882-8. PubMed ID: 20068265 [TBL] [Abstract][Full Text] [Related]
58. [Treatment of overactive urinary bladder with imperative urinary incontinence in women]. Neĭmark AI; Riapolova MV; Mel'nik MA Urologiia; 2010; (2):36-8. PubMed ID: 20967993 [TBL] [Abstract][Full Text] [Related]
59. [Efficacy and safety of solifenacin in daily clinical practice--clinical study phase IV]. Krhut J; Havránek O; Míka D; Fabisovský M; Valis P Ceska Gynekol; 2008 Dec; 73(6):370-5. PubMed ID: 19170373 [TBL] [Abstract][Full Text] [Related]
60. [Solifenacin in treatment of the overactive bladder syndrome--diagnosis, clinical management and results]. Slavov Ch; Popov E; Slavov S; Dimitrov R; Doganov N; Chernev T Akush Ginekol (Sofiia); 2010; 49(3):16-21. PubMed ID: 20734651 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]